Aducanumab: an uprising hope with vague horizons

Aducanumab: an uprising hope with vague horizons

Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the pathophysiology of AD, has inspired interest in targeted therapies, including monoclonal antibodies. Aducanumab acts as a fully human IgG1 monoclonal an...

Full description

Bibliographic Details
Main Authors: Delara Hazegh Fetratjoo, Alireza Kargar, Maryam Noroozian
Format: Article
Language:English
Published: SpringerOpen 2023-06-01
Series:The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Subjects:
Alzheimer’s disease
Aducanumab
Amyloid-beta
Monoclonal antibody
ARIA-E
ARIA-H
Online Access:https://doi.org/10.1186/s41983-023-00684-w

Internet

https://doi.org/10.1186/s41983-023-00684-w

Similar Items